Casdin Capital »

Neurogene shares owned by Casdin Capital

Quarter-by-quarter ownership of Neurogene (NGNE) shares owned by Casdin Capital from 13F filings

Historical chart of Casdin Capital investment in Neurogene

Tip: Access up to 7 years of quarterly data

All positions including Neurogene held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neurogene by Casdin Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $10M 525k 19.38

More positions owned by Casdin Capital

Revolution Medicines (RVMD)
Biolife Solutions Com New (BLFS)
Sarepta Therapeutics (SRPT)
Relay Therapeutics (RLAY)
Illumina Call Option (ILMN)
Structure Therapeutics Sponsored Ads Call Option (GPCR)
Intellia Therapeutics (NTLA)
Verve Therapeutics (VERV)
Alnylam Pharmaceuticals (ALNY)
Somalogic Class A Com
EXACT Sciences Corporation (EXAS)
Blueprint Medicines (BPMC)
Pliant Therapeutics (PLRX)
Denali Therapeutics (DNLI)
4d Molecular Therapeutics In (FDMT)

View all positions for Casdin Capital

Top funds holding Neurogene

EcoR1 Capital
Samsara BioCapital
Dr. Jeffrey R. Jay, M.D.
Redmile Group
Henderson Group
Cormorant Asset Management
Arrowpoint Asset Management
Casdin Capital
Avidity Partners Management
Baker Bros. Advisors
Walleye Trading Advisors
Nantahala Capital Management
Vanguard Group
Bank of America Corporation
Bessemer

View all funds holding Neurogene